NCT02234570View on ClinicalTrials.gov

Phase I Trial Evaluating the Safety and Pharmacokinetics of Oxfendazole

PHASE1CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

November 17, 2014

Primary Completion Date

November 24, 2015

Study Completion Date

November 24, 2015

Conditions
Neurocysticercosis
Interventions
DRUG

Oxfendazole

A benzimidazole carbamate antiparasitic drug. Oral Dose levels of 0.5,1, 3, 7.5, 15, 30, and 60 mg/kg will be evaluated sequentially, the dose increasing with each new cohort Group 1 to Group 7.

OTHER

Placebo

Normal Saline administered with an oral dosing syringe. Group 1- Group 6

Trial Locations (1)

52242-2600

University of Iowa - Vaccine Research and Education Unit, Iowa City

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT02234570 - Phase I Trial Evaluating the Safety and Pharmacokinetics of Oxfendazole | Biotech Hunter | Biotech Hunter